NPRA mission is to safeguard the nation’s health through scientific excellence in the regulatory control of medicinal products and cosmetics.
COVID-19
PRODUCT SEARCH
REPORTING OF SIDE EFFECTS TO MEDICINES OR VACCINES
Garis Panduan Penilaian Kesetaraan Taraf Amalan Perkilangan Baik (APB) Pengilang TMHS Luar Negara, Edisi Pertama, September 2024 |
Progestogens (Cyproterone Acetate, Medroxyprogesterone Acetate, Chlormadinone): Risk of Meningioma |
[Updated August 2024] Product Classification Form - NPRA/413/01-3 |
Pengemaskinian Drug Registration Guidance Document (DRGD) Berkaitan Keperluan Deklarasi Bahan Bersumberkan Haiwan Pada Label Produk |
Azacitidine (Injectable Formulation): Risk of Cutaneous Vasculitis |
12 Nov 2024; 08:00AM - 05:00PM MOPI Training 2024: Good Distribution Practice for the Regulated Industry |
15 Oct 2024; 08:00AM - 05:00PM MOPI Training 2024: A practical approach to ISO 13485 QMS for medical devices |
25 Sep 2024; 08:00AM - 05:00PM MOPI Training 2024: Contamination Control - How to Develop an Effective Contamination Control Strategy |
10 Sep 2024; 08:00AM - 05:00PM MOPI Training 2024: Supply chain management and Supplier QA program-Application of QRM principles |
27 Aug 2024; 08:00AM - 05:00PM MOPI Training 2024: Internal Audit – a key to effective Quality System |